BRAF V600E mutation analysis in papillary thyroid carcinomas by peptide nucleic acid clamp real-time PCR

Annals of Surgical Oncology

Volumn 20, Issue 3, 2013, Pages 759-766

  Jeong, Dongjun ^a   Jeong, Yujun ^a   Park, Ji Hye ^a   Han, Sun Wook ^a   Kim, Sung Yong ^a   Kim, Yeo Joo ^a   Kim, Sang Jin ^a   Hwangbo, Young ^a   Park, Soyoung ^a   Cho, Hyun Deuk ^a   Oh, Mee Hye ^a   Yang, Seung Ha ^a   Kim, Chang Jin ^a  

^a Soonchunhyang University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; GENOMIC DNA; PEPTIDE NUCLEIC ACID;

ADULT; ARTICLE; CANCER GENETICS; CANCER INVASION; CANCER SIZE; CANCER STAGING; DNA SEQUENCE; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; THYROID CARCINOMA;

CARCINOMA, PAPILLARY; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PEPTIDE NUCLEIC ACIDS; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; REAL-TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 84875222136     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2494-0     Document Type: Article

References (37)

1. IC Paterson R Greenlee D Adams Jones 1999 Thyroid cancer in Wales, 1985-1996: a cancer registry-based study Clin Oncol (R Coll Radiol) 11 245 251 10.1053/clon.1999.9057 1:STN:280:DyaK1Mvgs1Chsg%3D%3D
2. ID Hay EJ Bergstralh JR Goellner JR Ebersold CS Grant 1993 Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989 Surgery. 114 1050 1057 8256208 1:STN:280:DyaK2c%2FnvVantA%3D%3D
3. Y Cohen M Xing E Mambo, et al. 2003 BRAF mutation in papillary thyroid carcinoma J Natl Cancer Inst. 95 625 627 12697856 10.1093/jnci/95.8.625 1:CAS:528:DC%2BD3sXjtFWqsbw%3D
4. X Xu RM Quiros P Gattuso KB Ain RA Prinz 2003 High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines Cancer Res. 63 4561 4567 12907632 1:CAS:528:DC%2BD3sXmtFers7Y%3D
5. T Fukushima S Suzuki M Mashiko, et al. 2003 BRAF mutations in papillary carcinomas of the thyroid Oncogene. 22 6455 6457 14508525 10.1038/sj.onc.1206739 1:CAS:528:DC%2BD3sXnsFantrk%3D
6. M Xing WH Westra RP Tufano, et al. 2005 BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer J Clin Endocrinol Metab. 90 6373 6379 16174717 10.1210/jc.2005-0987 1:CAS:528:DC%2BD2MXhtlaltL7I
7. L Fugazzola D Mannavola V Cirello, et al. 2004 BRAF mutations in an Italian cohort of thyroid cancers Clin Endocrinol (Oxf). 61 239 243 10.1111/j.1365-2265.2004.02089.x 1:CAS:528:DC%2BD2cXnslWlt70%3D
8. KH Kim DW Kang SH Kim IO Seong DY Kang 2004 Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population Yonsei Med J. 45 818 821 15515191 1:CAS:528:DC%2BD2cXhtVKitbvO
9. V600E mutations in thyroid tumors Lab Invest. 85 1065 1075 15980887 10.1038/labinvest.3700306 1:CAS:528:DC%2BD2MXos1Wksbs%3D
10. E Kebebew J Weng J Bauer, et al. 2007 The prevalence of prognostic value of BRAF mutation in thyroid cancer Ann Surg. 246 466 471 17717450 10.1097/SLA.0b013e318148563d
11. EV Vasil'ev PO Roumiantsev VA Saenko, et al. 2004 Molecular analysis of structural abnormalities in papillary thyroid carcinoma genome Mol Biol. 38 538 548 10.1023/B:MBIL.0000037006.90193.f6
12. V600E mutation and X-linked inhibitor of apoptosis expression in papillary thyroid carcinoma Thyroid. 19 347 354 19355825 10.1089/thy.2008.0246 1:CAS:528: DC%2BD1MXkt1CgsLk%3D
13. V600E mutation useful as a predictor of preoperative risk in papillary thyroid cancer? Am J Surg. 203 436 441 21803329 10.1016/j.amjsurg.2011.02.013 1:CAS:528: DC%2BC38XksFehu7Y%3D
14. ET Kimura MN Nikiforova Z Zhu JA Knauf YE Nikiforov JA Fagin 2003 High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma Cancer Res. 63 1454 1457 12670889 1:CAS:528: DC%2BD3sXisFaisLs%3D
15. V599E mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas J Clin Endocrinol Metab. 89 2414 2420 15126572 10.1210/jc.2003-031425 1:CAS:528:DC%2BD2cXjvFyruro%3D
16. A Perren S Schmid T Locher, et al. 2004 BRAF and endocrine tumors: mutations are frequent in papillary thyroid carcinomas, rare in endocrine tumors of the gastrointestinal tract and not detected in other endocrine tumors Endocr Relat Cancer. 11 855 860 15613458 10.1677/erc.1.00841 1:CAS:528: DC%2BD2MXhtVart7s%3D
17. V Trovisco I Vieira de Castro P Soares, et al. 2004 BRAF mutations are associated with some histological types of thyroid papillary carcinoma J Pathol. 202 247 251 14743508 10.1002/path.1511 1:CAS:528:DC%2BD2cXhvVKjtLo%3D
18. P Soares V Trovisco AS Rocha, et al. 2003 BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC Oncogene. 22 4578 4580 12881714 10.1038/sj.onc.1206706 1:CAS:528:DC%2BD3sXls1yntL0%3D
19. V600E mutation in the pathogenesis of the large series of papillary thyroid carcinoma in Czech Republic J Endocrinol Invest. 33 318 324 20009493 1:CAS:528: DC%2BC3cXptl2ltL0%3D
20. MN Nikiforova ET Kimura M Gandhi, et al. 2003 BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas J Clin Endocrinol Metab. 88 5399 5404 14602780 10.1210/jc.2003-030838 1:CAS:528: DC%2BD3sXptVyntrs%3D
21. V600E activating mutation in papillary thyroid carcinoma using PCR with allele-specific fluorescent probe melting curve analysis J Clinl Pathol. 60 1211 1215 10.1136/jcp.2006.040105 1:CAS:528:DC%2BD2sXhsVelu7fP
22. J Kim AE Giuliano RR Turner, et al. 2006 Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma Ann Surg. 244 799 804 17060774 10.1097/01.sla.0000224751.80858.13
23. MR Sapio D Posca G Troncone, et al. 2006 Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA) Eur J Endocrinol. 154 341 348 16452550 10.1530/eje.1.02072 1:CAS:528: DC%2BD28XitlGltL4%3D
24. T1796A mutation in fine-needle aspirated thyroid carcinoma cells Thyroid. 14 910 915 15671769 10.1089/thy.2004.14.910 1:CAS:528:DC%2BD2cXhtVGmt7bF
25. V600E mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis Thyroid. 19 137 141 19014278 10.1089/thy.2008.0144
26. E Lyon CT Wittwer 2009 LightCycler technology in molecular diagnostics J Mol Diagn. 11 93 101 19196999 10.2353/jmoldx.2009.080094 1:CAS:528: DC%2BD1MXjs12qs70%3D
27. DB Demers ET Curry M Egholm AC Sozer 1995 Enhanced PCR amplification of VNTR locus D1S80 using peptide nucleic acid (PNA) Nucleic Acids Res. 23 3050 3055 7659530 10.1093/nar/23.15.3050 1:CAS:528:DyaK2MXnvVekurc%3D
28. D Jeong Y Jeong J Lee, et al. 2011 Rapid and sensitive detection of KRAS mutation by peptide nucleic acid-based real-time PCR clamping: a comparison with direct sequencing between fresh tissue and formalin-fixed and paraffin embedded tissue of colorectal cancer Korean J Pathol. 45 151 159 10.4132/KoreanJPathol. 2011.45.2.151
29. EM Kyger MD Krevolin MJ Powell 1998 Detection of the hereditary hemochromatosis gene mutation by real-time fluorescence polymerase chain reaction and peptide nucleic acid clamping Anal Biochem. 260 142 148 9657870 10.1006/abio.1998.2687 1:CAS:528:DyaK1cXks1ygtbw%3D
30. B Taback AJ Bilchik S Saha, et al. 2004 Peptide nucleic acid clamp PCR: a novel K-ras mutation detection assay for colorectal cancer micrometastases in lymph nodes Int J Cancer. 111 409 414 15221969 10.1002/ijc.20268 1:CAS:528:DC%2BD2cXmtlKlsrw%3D
31. C Thiede E Bayerdörffer R Blasczyk B Wittig A Neubauer 1996 Simple and sensitive detection of mutations in the ras proto-oncogenes using PNA-mediated PCR clamping Nucleic Acids Res. 24 983 984 8600471 10.1093/nar/24.5.983 1:CAS:528:DyaK28Xhs1Cktrg%3D
32. H Guan M Ji R Bao, et al. 2009 Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer J Clin Endocrinol Metab. 94 1612 1617 19190105 10.1210/jc.2008-2390 1:CAS:528:DC%2BD1MXlvVCqt70%3D
33. JY Kim SJ Moon KR Kim, et al. 2000 Dietary iodine intake and urinary iodine excretion in normal Korean adults Yonsei Med J. 39 355 362
34. JY Kim KR Kim 2000 Dietary iodine intake and urinary iodine excretion in patients with thyroid diseases Yonsei Med J. 41 22 28 10731915 1:CAS:528:DC%2BD3cXitFyhs7o%3D
35. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Globocan 2008 v1.2, Cancer incidence and mortality worldwide. IARC CancerBase 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.fr.
36. T Ahmad T Eisen 2004 Kinase inhibition with BAY 43-9006 in renal cell carcinoma Clin Cancer Res. 10 18 Pt 2 6388S 6392S 15448036 10.1158/1078-0432. CCR-040028 1:CAS:528:DC%2BD2cXnvVOjtrw%3D
37. E Sala L Mologni S Truffa C Gactano GE Bollag C Gambacorti-Passerini 2008 BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells Mol Cancer Res. 6 751 759 18458053 10.1158/1541-7786.MCR-07-2001 1:CAS:528:DC%2BD1cXmt1OjsL0%3D